November 21, 2017 10:01 PM ET

Pharmaceuticals

Company Overview of NantBioscience, Inc.

Company Overview

NantBioscience, Inc. develops molecularly targeted drugs based on the profile of the patient's tumor and drugs that remediate the activities of the often mutated tumor suppressor, p53. It develops a pipeline of nab-based molecules, and inhibitors of proteins which drive tumor growth. It has strategic alliances with National Cancer Institute. The company was incorporated in 2013 and is based in Culver City, California. NantBioscience, Inc. operates as a subsidiary of NantWorks, LLC.

9920 Jefferson Boulevard

Culver City, CA 90232

United States

Founded in 2013

Phone:

310-853-7888

Key Executives for NantBioscience, Inc.

Founder and Director
Age: 64
Compensation as of Fiscal Year 2017.

NantBioscience, Inc. Key Developments

NantBioscience, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 09:00 AM

NantBioscience, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-09-2017 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, California, United States. Speakers: Patrick Soon-Shiong, CEO.

NantBioScience Signs Cooperative Research and Development Agreement with the National Cancer Institute

NantBioScience has signed a cooperative research and development agreement with the National Cancer Institute. According to the agreement, NantBioScience and its affiliates, including NantKwest will collaborate to further develop their proprietary recombinant NK and monoclonal antibodies in monotherapy and in combination immunotherapies. NantBioScience and NantKwest will be collaborating with Dr. Jeffrey Schlom, chief of the Laboratory of Tumor Immunology and Biology, NCI, and Dr. James Gulley, chief of the Genitourinary Malignancies Branch, NCI, and their teams to expand the preclinical and clinical development of recombinant NK cells and monoclonal antibodies, for use in combinations with other immunotherapeutics, such as vaccines and immune modulators, and other forms of cancer therapy.

NantBioScience and NantKwest Partner with the National Cancer Institute to Further Develop Recombinant NK Cells and Monoclonal Antibodies as Monotherapies and Combination Cancer Immunotherapies

NantBioScience announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), an Institute of the National Institutes of Health (NIH). Under the CRADA, NantBioScience and its affiliates, such as NantKwest, will work together to further develop their proprietary recombinant NK and monoclonal antibodies in monotherapy and in combination immunotherapies. NantBioScience and NantKwest will be working with Dr. Jeffrey Schlom, Chief of the Laboratory of Tumor Immunology and Biology, NCI, and Dr. James Gulley, Chief of the Genitourinary Malignancies Branch, NCI, and their teams to expand the preclinical and clinical development of recombinant NK cells and monoclonal antibodies, for use in combinations with other immunotherapeutics, such as vaccines and immune modulators, and other forms of cancer therapy. Both in vitro and in vivo preclinical testing will be conducted to further develop NantBioScience's and NantKwest's proprietary agents, and Phase I and II clinical studies will be carried out both at the NIH Clinical Center and in collaboration with investigators at extramural Cancer Centers. NantBioScience and NantKwest will manufacture the immunotherapeutic products for use in these studies, and the NCI will conduct both preclinical and clinical Phase I and II studies, which will potentially provide the rationale for randomized Phase III studies. The NCI will also carry out extensive immune analyses of the immune responses of patients undergoing clinical studies under this CRADA.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
\
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
The Advertising Council, Inc. United States
NYC2012, Inc. United States
Tax Management Inc United States
John F. Kennedy Center For The Performing Arts United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NantBioscience, Inc., please visit --. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.